Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles

Journal of Medicinal Chemistry

Volumn 49, Issue 26, 2006, Pages 7868-7876

  Boschelli, Diane H ^a   Wu, Biqi ^a   Ye, Fei ^a   Wang, Yan ^a   Golas, Jennifer M ^a   Lucas, Judy ^a   Boschelli, Frank ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2,4 DICHLORO 5 METHOXYPHENYL)AMINO] 6 METHOXY 7 [5 [(4 METHYLPIPERAZIN 1 YL)METHYL] 3 FURYL] 3 QUINOLINECARBONITRILE; ABELSON KINASE; BOSUTINIB; DASATINIB; IMATINIB; PROTEIN KINASE LCK; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MICE; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845962586     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061031t     Document Type: Article

References (37)

1. Martin, G. S. The road to Src. Oncogene 2004, 23, 7910-7917.
2. Parsons, S. J.; Parsons, J. T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23, 7906-7909.
3. Summy, J. M.; Gallick, G. E. Treatment for advanced tumors: SRC reclaims center stage. Clin. Cancer Res. 2006, 12, 1398-1401.
4. Chen, T.; George, J. A.; Taylor, C. C. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anti-Cancer Drugs 2006, 17, 123-131.
5. Summy, J. M.; Gallick, G. E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003, 22, 337-358.
6. Avizienyte, E.; Wyke, A. W.; Jones, R. J.; McLean, G. W.; Westhoff, M. A.; Brunton, V. G.; Frame, M. C. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat. Cell Biol. 2002, 4, 632-638.
7. Weis, S.; Cui, J.; Barnes, L.; Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 2004, 167, 223-229.
8. Criscuoli, M. L.; Nguyen, M.; Eliceiri, B. P. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005, 105, 1508-1514.
9. Yezhelyev, M. V.; Koehl, G.; Guba, M.; Brabletz, T.; Jauch, K. W.; Ryan, A.; Barge, A.; Green, T.; Fennell, M.; Bruns, C. J. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 2004, 10, 8028-8036.
10. Trevino, J. G.; Summy, J. M.; Lesslie, D. P.; Parikh, N. U.; Hong, D. S.; Lee, F. Y.; Donato, N. J.; Abbruzzese, J. L.; Baker, C. H.; Gallick, G. E. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 2006, 168, 962-972.
11. Nam, J. S.; Ino, Y.; Sakamoto, M.; Hirohashi, S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 2002, 8, 2430-2436.
12. Summy, J. M.; Trevino, J. G.; Lesslie, D. P.; Baker, C. H.; Shakespeare, W. C.; Wang, Y.; Sundaramoorthi, R.; Metcalf, C. A., III; Keats, J. A.; Sawyer, T. K.; Gallick, G. E. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol. Cancer Ther. 2005, 4, 1900-1911.
13. Hiscox, S.; Morgan, L.; Green, T. P.; Barrow, D.; Gee, J.; Nicholson, R. I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 2006, 97, 263-274.
14. Zheng, R.; Yano, S.; Matsumori, Y.; Nakataki, E.; Muguruma, H.; Yoshizumi, M.; Sone, S. Src tyrosine kinase inhibitor, M475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clin. Exp. Metastasis 2005, 22, 195-204.
15. Rucci, N.; Recchia, I.; Angelucci, A.; Alamanou, M.; Del Fattore, A.; Fortunati, D.; Susa, M.; Fabbro, D.; Bologna, M.; Teti, A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: Implications for therapy. J. Pharm. Exp. Ther. 2006, 318, 161-172.
16. Boschelli, D. H. Dual inhibitors of Src and Abl tyrosine kinases. Drug Des. Rev.-Online 2004, 1, 203-214.
17. Cortes, J.; Kantarjian, H. New targeted approaches in chronic myeloid leukemia. J. Clin. Oncol. 2005, 23, 6316-6324.
18. Manley, P. W.; Cowan-Jacob, S. W.; Mestan, J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 2005, 1754, 3-13.
19. Martinelli, G.; Soverini, S.; Rosti, G.; Baccarani, M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 2005, 19, 1872-1879.
20. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Morris, D.; Sawyers, C. L. Overriding Imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305, 399-402.
21. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Baish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A. M.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M.-L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-chloro- 6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47, 6658-6661.
22. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis. A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354, 2531-2541.
23. U.S. Food and Drug Administration. FDA gives rapid approval for a new treatment for a rare type of leukemia, http://www.fda.gov/bbs/topics/NEWS/2006/ NEW01400.html (accessed 2006).
24. Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 2001, 44, 3965-3977.
25. Golas, J. M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D. H.; Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003, 63, 375-381.
26. Golas, J. M.; Lucas, J.; Etienne, C.; Golas, J.; Discafani, C.; Sridharan, L.; Boghaert, E.; Arndt, K.; Ye, F.; Boschelli, D. H.; Li, F.; Titsch, C.; Huselton, C.; Chaudhary, I.; Boschelli, F. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 2005, 65, 5358-5364.
27. Coluccia, A. M. L.; Benati, D.; Dekhil, H.; De Filippo, A.; Lan, C.; Gambacorti-Passerini, C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of β-catenin and its nuclear signaling. Cancer Res. 2006, 66, 2279-2286.
28. Boschelli, D. H.; Wang, D. Y.; Ye, F.; Yamashita, A.; Zhang, N.; Powell, D.; Weber, J.; Boschelli, F. Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles. Bioorg. Med. Chem. Lett. 2002, 12, 2011-2014.
29. Berger, D.; Dutia, M.; Powell, D.; Wissner, A.; DeMorin, F.; Raifeld, Y.; Weber, J.; Boschelli, F. Substituted 4-anilino-7-phenyl-3- quinolinecarbonitriles as Src kinase inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 2989-2992.
30. Yamamoto, M.; Izukawa, H.; Saiki, M.; Yamada, K. Oxidative substitution reactions of organotin compounds with lead tetraacetate. J. Chem. Soc., Chem. Commun. 1988, 8, 560-561.
31. Sutherland, K. W.; Feigelson, G. B.; Boschelli, D. H.; Blum, D. M.; Strong, H. L. Process for the preparation of 4-amino-3-quinolinecarbonitriles and 7-aminothieno[3,2-b]pyridine-6-carbonitriles, US 2005043537, 2005.
32. Barrios Sosa, A. C.; Boschelli, D. H.; Wu, B.; Wang, Y.; Golas, J. M. Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: Identification of a subnanomolar Src kinase inhibitor. Bioorg. Med. Chem. Lett. 2005, 15, 1743-1747.
33. Barrios Sosa, A. C.; Boschelli, D. H.; Ye, F.; Golas, J. M.; Boschelli, F. Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles. Bioorg. Med. Chem. Lett. 2004, 14, 2155-2158.
34. Boschelli, D. H.; Ye, F.; Wu, B.; Wang, Y. D.; Barrios Sosa, A. C.; Yaczko, D.; Powell, D.; Golas, J. M.; Lucas, J.; Boschelli, F. Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3- quinolinecarbonitriles on the inhibition of Src kinase activity. Bioorg. Med. Chem. Lett. 2003, 13, 3797-3800.
35. Boschelli, D. H.; Wang, Y. D.; Johnson, S.; Wu, B.; Ye, F.; Barrios Sosa, A. C.; Golas, J. M.; Boschelli, F. 7-Alkoxy-4-phenylamino-3- quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J. Med. Chem. 2004, 47, 1599-1601.
36. Boschelli, D. H.; Wang, Y. D.; Ye, F.; Wu, B.; Zhang, N.; Dutia, M.; Powell, D. W.; Wissner, A.; Arndt, K.; Weber, J. M.; Boschelli, F. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3- quinolinecarbonitriles. J. Med. Chem. 2001, 44, 822-833.
37. Boschelli, D. H.; Wu, B.; Barrios Sosa, A. C.; Durutlic, H.; Chen, J. J.; Wang, Y.; Golas, J. M.; Lucas, J.; Boschelli, F. Synthesis and Src kinase inhibitory activity of 2-phenyl and 2-thienyl-7-phenylaminothieno[3,2-b] pyridine-6-carbonitriles. J. Med. Chem. 2005, 48, 3891-3902.